Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOUBLE-001 trial of hepatic arterial camrelizumab plus mFOLFOX and sorafenib in advanced unresectable hepatocellular carcinoma
ChiCTR2100041874Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, oxaliplatin, fluorouracil, folinic acid and sorafenib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Started Jan 2021; status: recruiting.
02
Drugs
camrelizumaboxaliplatinfluorouracilfolinic acidsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100041874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041874.